Researchers discover epigenetic mechanism underlying ischemic cardiomyopathy

Researchers at the University of Alabama at Birmingham have shed light on an epigenetic reprogramming mechanism that underlies the development of ischemic cardiomyopathy.

Shutterstock | Sebastian Kaulitzki

The finding, which has recently been published in Nature - Laboratory Investigation, is hoped to pave the way for personalized care for people with the condition.

Ischemic cardiomyopathy, which is caused by restricted blood flow to the coronary arteries, is the most common form of congestive heart failure, yet it can only be managed with symptomatic treatment because the cause of the condition is not known.

Now, Adam Wende and colleagues have shown that the epigenetic changes seen in ischemic cardiomyopathy probably reprogram the heart's metabolism and change the organ’s cellular remodeling.

The team compared heart tissue samples taken from the left ventricles of five ischemic cardiomyopathy patients with tissue taken from six non-ischemic cardiomyopathy patients.

One well-known epigenetic change is the addition to or removal of methyl groups from cytosine, one of the four main bases that make up DNA. Hypermethylation is associated with reduced gene expression and hypomethylation with increased gene expression.

The team found that in the heart tissue of ischemic cardiomyopathy patients, there was an epigenetic signature that differed to the heart tissue of non-ischemic cardiomyopathy patients. This signature was found to represent a well-established metabolic change, where the heart switches from using oxygen to produce energy to an anaerobic mechanism.

"Altogether, we believe that epigenetic changes encode a so-called 'metabolic plasticity' in failing hearts, the reversal of which may repair the ischemic and failing heart," says Wende.

Wende and colleagues found that hypermethylation was associated with a decreased expression of the genes involved in oxidative metabolism. An upstream regulator of metabolic gene expression, KLF15, was found to be suppressed by an epigenetic regulator called EZH2. The team also found that genes involved in anaerobic glycolytic metabolism were hypomethylated.

This involvement of EZH2 could potentially provide a molecular target for further research into precision-based heart disease treatments.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 17). Researchers discover epigenetic mechanism underlying ischemic cardiomyopathy. News-Medical. Retrieved on September 12, 2025 from https://www.news-medical.net/news/20180813/Researchers-discover-epigenetic-mechanism-underlying-ischemic-cardiomyopathy.aspx.

  • MLA

    Robertson, Sally. "Researchers discover epigenetic mechanism underlying ischemic cardiomyopathy". News-Medical. 12 September 2025. <https://www.news-medical.net/news/20180813/Researchers-discover-epigenetic-mechanism-underlying-ischemic-cardiomyopathy.aspx>.

  • Chicago

    Robertson, Sally. "Researchers discover epigenetic mechanism underlying ischemic cardiomyopathy". News-Medical. https://www.news-medical.net/news/20180813/Researchers-discover-epigenetic-mechanism-underlying-ischemic-cardiomyopathy.aspx. (accessed September 12, 2025).

  • Harvard

    Robertson, Sally. 2019. Researchers discover epigenetic mechanism underlying ischemic cardiomyopathy. News-Medical, viewed 12 September 2025, https://www.news-medical.net/news/20180813/Researchers-discover-epigenetic-mechanism-underlying-ischemic-cardiomyopathy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients